Arming immune cells with antibodies 

Acepodia is developing cancer immunotherapy based on its ACC™ (Antibody Cell-Conjugation) technology platform. Using ACC™ technology, we arm immune cells with antibodies to form Antibody-Conjugated Effector cells (ACE™) to direct and evoke immune responses to eradicate cancer cells.

Synergistic with CAR technology

ACC™ can equip CAR engineered immune cells (e.g., CAR-NK) with antibodies, bringing antibody selection and dose titration capabilities. The synergy between ACC™ and CAR technology will potentially increase the effectiveness of future immunotherapy.

Validated cells present promising treatments

The ACE1702 is currently the leading candidate in Acepodia's pipeline. ACE1702 has been validated in-vitro and in-vivo, showing promise for success. ACE1702 is currently on track to enter Phase 1 clinical trials for HER2+ gynecologic cancers.